title: A phase I study of myo-inositol for lung cancer chemoprevention.
abstract: BACKGROUND
  A phase I, open-label, multiple dose, dose-escalation clinical study was conducted to assess the safety, tolerability, maximum tolerated dose, and potential chemopreventive effect of myo-inositol in smokers with bronchial dysplasia.
  
  
  METHODS
  Smokers between 40 and 74 years of age with >or= 30 pack-years of smoking history and one or more sites of bronchial dysplasia were enrolled. A dose escalation study ranging from 12 to 30 g/d of myo-inositol for a month was first conducted in 16 subjects to determine the maximum tolerated dose. Ten new subjects were then enrolled to take the maximum tolerated dose for 3 months. The potential chemopreventive effect of myo-inositol was estimated by repeat autofluorescence bronchoscopy and biopsy.
  
  
  RESULTS
  The maximum tolerated dose was found to be 18 g/d. Side effects, when present, were mild and mainly gastrointestinal in nature. Using the regression rate of the placebo subjects from a recently completed clinical trial with the same inclusion/exclusion criteria as a comparison, a significant increase in the rate of regression of preexisting dysplastic lesions was observed (91% versus 48%; P = 0.014). A statistically significant reduction in the systolic and diastolic blood pressures by an average of 10 mm Hg was observed after taking 18 g/d of myo-inositol for a month or more.
  
  
  CONCLUSIONS
  myo-Inositol in a daily dose of 18 g p.o. for 3 months is safe and well tolerated. The potential chemopreventive effect as well as other health benefits such as reduction in blood pressure should be investigated further.
authors.affiliation: Department of Respiratory Medicine, British Columbia Cancer Agency, British Columbia, Canada. slam@bccancer.bc.ca
authors.forename: Stephen
authors.initials: S
authors.lastname: Lam
authors.forename: Annette
authors.initials: A
authors.lastname: McWilliams
authors.forename: Jean
authors.initials: J
authors.lastname: LeRiche
authors.forename: Calum
authors.initials: C
authors.lastname: MacAulay
authors.forename: Lee
authors.initials: L
authors.lastname: Wattenberg
authors.forename: Eva
authors.initials: E
authors.lastname: Szabo
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D018890:Chemoprevention; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007294:Inositol / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D014803:Vitamin B Complex / Q000627:therapeutic use*
chemical_list: D014803:Vitamin B Complex; D007294:Inositol